Clinical Trials Logo

Primary Visceral Leishmaniasis clinical trials

View clinical trials related to Primary Visceral Leishmaniasis.

Filter by:
  • None
  • Page 1

NCT ID: NCT05957978 Recruiting - Clinical trials for Primary Visceral Leishmaniasis

LXE408 for Treatment of Visceral Leishmaniasis in Ethiopia, a Proof of Concept Study

Start date: April 3, 2024
Phase: Phase 2
Study type: Interventional

This is a randomized, open-label, phase II, single-centre study, with one LXE408 regimen and one calibrator arm with the standard of care SSG combined with PM, to be conducted in male and female adult (≥18 years and <45 years) patients with confirmed primary visceral leishmaniasis in Ethiopia.

NCT ID: NCT05593666 Recruiting - Clinical trials for Primary Visceral Leishmaniasis

A Phase II, Multicentre, Randomized, Two-arm Blinded Study to Assess the Efficacy and Safety of Two LXE408 Regimens for Treatment of Patients With Primary Visceral Leishmaniasis

Start date: December 27, 2022
Phase: Phase 2
Study type: Interventional

This is a phase II, multicentre, randomized, two-arm blinded study with an open label calibrator arm in adults and adolescents (≥12 years) with confirmed primary VL.

NCT ID: NCT01067443 Completed - Clinical trials for Primary Visceral Leishmaniasis

Clinical Trial to Assess the Safety and Efficacy of Sodium Stibogluconate (SSG) and AmBisome® Combination, Miltefosine and AmBisome® and Miltefosine Alone for the Treatment Visceral Leishmaniasis in Eastern Africa

Start date: March 2010
Phase: Phase 2
Study type: Interventional

This study is to assess if shorter combinations of SSG plus single dose AmBisome®, Miltefosine plus single dose AmBisome® and Miltefosine alone are effective in treating visceral leishmaniasis in Eastern Africa.